vs
CNA FINANCIAL CORP（CNA）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是CNA FINANCIAL CORP的1.6倍（$622.0M vs $389.0M），CNA FINANCIAL CORP净利率更高（77.6% vs 34.4%，领先43.2%），Royalty Pharma plc同比增速更快（4.8% vs -2.0%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -2.2%）
CNA金融公司是总部位于美国伊利诺伊州芝加哥的金融企业，旗下核心子公司大陆意外伤害保险公司成立于1897年，大陆保险公司的历史则可追溯至1853年，当前母公司CNA于1967年正式注册成立，在保险及金融服务领域拥有深厚的行业积淀。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
CNA vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.6倍
$389.0M
营收增速更快
RPRX
高出6.8%
-2.0%
净利率更高
CNA
高出43.2%
34.4%
两年增速更快
RPRX
近两年复合增速
-2.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $389.0M | $622.0M |
| 净利润 | $302.0M | $214.2M |
| 毛利率 | — | — |
| 营业利润率 | 97.2% | 62.4% |
| 净利率 | 77.6% | 34.4% |
| 营收同比 | -2.0% | 4.8% |
| 净利润同比 | 1338.1% | 2.9% |
| 每股收益（稀释后） | $1.11 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CNARPRX
| Q4 25 | $389.0M | $622.0M | ||
| Q3 25 | $393.0M | $609.3M | ||
| Q2 25 | $398.0M | $578.7M | ||
| Q1 25 | $397.0M | $568.2M | ||
| Q4 24 | $397.0M | $593.6M | ||
| Q3 24 | $401.0M | $564.7M | ||
| Q2 24 | $404.0M | $537.3M | ||
| Q1 24 | $407.0M | $568.0M |
净利润CNARPRX
| Q4 25 | $302.0M | $214.2M | ||
| Q3 25 | $403.0M | $288.2M | ||
| Q2 25 | $299.0M | $30.2M | ||
| Q1 25 | $274.0M | $238.3M | ||
| Q4 24 | $21.0M | $208.2M | ||
| Q3 24 | $283.0M | $544.0M | ||
| Q2 24 | $317.0M | $102.0M | ||
| Q1 24 | $338.0M | $4.8M |
营业利润率CNARPRX
| Q4 25 | 97.2% | 62.4% | ||
| Q3 25 | — | 70.1% | ||
| Q2 25 | 95.5% | 36.3% | ||
| Q1 25 | 87.9% | 94.0% | ||
| Q4 24 | 5.3% | 60.9% | ||
| Q3 24 | 90.0% | — | ||
| Q2 24 | 99.5% | 50.2% | ||
| Q1 24 | — | -13.0% |
净利率CNARPRX
| Q4 25 | 77.6% | 34.4% | ||
| Q3 25 | 102.5% | 47.3% | ||
| Q2 25 | 75.1% | 5.2% | ||
| Q1 25 | 69.0% | 41.9% | ||
| Q4 24 | 5.3% | 35.1% | ||
| Q3 24 | 70.6% | 96.3% | ||
| Q2 24 | 78.5% | 19.0% | ||
| Q1 24 | 83.0% | 0.8% |
每股收益（稀释后）CNARPRX
| Q4 25 | $1.11 | $0.49 | ||
| Q3 25 | $1.48 | $0.67 | ||
| Q2 25 | $1.10 | $0.07 | ||
| Q1 25 | $1.00 | $0.55 | ||
| Q4 24 | $0.07 | $0.46 | ||
| Q3 24 | $1.04 | $1.21 | ||
| Q2 24 | $1.17 | $0.23 | ||
| Q1 24 | $1.24 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $618.7M |
| 总债务越低越好 | $3.0B | $9.0B |
| 股东权益账面价值 | $11.6B | $9.7B |
| 总资产 | $69.4B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.26× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资CNARPRX
| Q4 25 | — | $618.7M | ||
| Q3 25 | — | $938.9M | ||
| Q2 25 | — | $631.9M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $929.0M | ||
| Q3 24 | — | $950.1M | ||
| Q2 24 | — | $1.8B | ||
| Q1 24 | — | $843.0M |
总债务CNARPRX
| Q4 25 | $3.0B | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | $3.0B | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益CNARPRX
| Q4 25 | $11.6B | $9.7B | ||
| Q3 25 | $11.3B | $9.6B | ||
| Q2 25 | $10.7B | $9.5B | ||
| Q1 25 | $10.3B | $9.8B | ||
| Q4 24 | $10.5B | $10.3B | ||
| Q3 24 | $10.8B | $10.3B | ||
| Q2 24 | $9.9B | $9.8B | ||
| Q1 24 | $9.7B | $9.9B |
总资产CNARPRX
| Q4 25 | $69.4B | $19.6B | ||
| Q3 25 | $69.8B | $19.3B | ||
| Q2 25 | $68.9B | $18.3B | ||
| Q1 25 | $67.3B | $17.6B | ||
| Q4 24 | $66.5B | $18.2B | ||
| Q3 24 | $67.4B | $18.0B | ||
| Q2 24 | $65.2B | $17.7B | ||
| Q1 24 | $65.1B | $16.1B |
负债/权益比CNARPRX
| Q4 25 | 0.26× | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | 0.28× | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $570.0M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $542.0M | — |
| 自由现金流率自由现金流/营收 | 139.3% | — |
| 资本支出强度资本支出/营收 | 7.2% | — |
| 现金转化率经营现金流/净利润 | 1.89× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $2.4B | — |
8季度趋势，按日历期对齐
经营现金流CNARPRX
| Q4 25 | $570.0M | $827.1M | ||
| Q3 25 | $720.0M | $702.6M | ||
| Q2 25 | $562.0M | $364.0M | ||
| Q1 25 | $638.0M | $596.1M | ||
| Q4 24 | $703.0M | $742.5M | ||
| Q3 24 | $748.0M | $703.6M | ||
| Q2 24 | $616.0M | $658.2M | ||
| Q1 24 | $504.0M | $664.6M |
自由现金流CNARPRX
| Q4 25 | $542.0M | — | ||
| Q3 25 | $704.0M | — | ||
| Q2 25 | $538.0M | — | ||
| Q1 25 | $620.0M | — | ||
| Q4 24 | $665.0M | — | ||
| Q3 24 | $730.0M | — | ||
| Q2 24 | $597.0M | — | ||
| Q1 24 | $484.0M | — |
自由现金流率CNARPRX
| Q4 25 | 139.3% | — | ||
| Q3 25 | 179.1% | — | ||
| Q2 25 | 135.2% | — | ||
| Q1 25 | 156.2% | — | ||
| Q4 24 | 167.5% | — | ||
| Q3 24 | 182.0% | — | ||
| Q2 24 | 147.8% | — | ||
| Q1 24 | 118.9% | — |
资本支出强度CNARPRX
| Q4 25 | 7.2% | — | ||
| Q3 25 | 4.1% | — | ||
| Q2 25 | 6.0% | — | ||
| Q1 25 | 4.5% | — | ||
| Q4 24 | 9.6% | — | ||
| Q3 24 | 4.5% | — | ||
| Q2 24 | 4.7% | — | ||
| Q1 24 | 4.9% | — |
现金转化率CNARPRX
| Q4 25 | 1.89× | 3.86× | ||
| Q3 25 | 1.79× | 2.44× | ||
| Q2 25 | 1.88× | 12.06× | ||
| Q1 25 | 2.33× | 2.50× | ||
| Q4 24 | 33.48× | 3.57× | ||
| Q3 24 | 2.64× | 1.29× | ||
| Q2 24 | 1.94× | 6.45× | ||
| Q1 24 | 1.49× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CNA
暂无分部数据
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
